Suggested Remit: To appraise the clinical and cost effectiveness of avelumab within its marketing authorisation for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer.
Status In progress
Decision Selected
Process TA
ID number 1261

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
27 March 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer ID1261. We have recently invited stakeholders to respond to a written consultation on the draft scope. On receiving updated regulatory timing information from the company that is developing avelumab, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently, the consultation on the draft scope will be closed. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on
17 January 2020 Following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early June 2020 when we will write to you about how you can get involved.
09 February 2018 In progress. Topic referred 22 July 2016

For further information on our processes and methods, please see our CHTE processes and methods manual